Last updated: February 11, 2026
What is the current investment landscape for sulfinpyrazone?
Sulfinpyrazone is a uricosuric agent traditionally used in managing gout by enhancing renal uric acid excretion. The drug's market presence has diminished due to the emergence of newer therapies, yet it retains niche indications and off-label applications. Market data indicates limited ongoing commercial activity, with no recent significant patent filings or approvals in major markets.
The drug’s candidate profile suggests low current market valuation but potential for repositioning if new therapeutic roles are identified. Its status as an off-patent medication implies limited exclusivity, increasing competition and reducing pricing power.
What are the key regulatory and patent considerations?
Patent Landscape
- The original patent for sulfinpyrazone expired decades ago. No recent patent filings or extensions are publicly documented.
- Patent expiry exposes the drug to generic competition, constraining pricing and margins for branded formulations.
Regulatory Status
- Approved by the U.S. FDA in 1956; unrenewed and not under current active patent protections.
- Market approvals persist for some regions, but most regulatory agencies classify sulfinpyrazone as off-label or legacy medication.
Financial and Commercial Fundamentals
Market Size and Dynamics
| Indicator |
Data |
| Global gout market size |
Estimated at $1.8 billion in 2022 (Grand View Research[1]) |
| Sulfinpyrazone market share |
Less than 2% due to obsolescence; limited sales in niche use |
| Main competitors |
Allopurinol, febuxostat, pegloticase |
Revenue Analysis
- Limited direct sales revenues attributable to sulfinpyrazone.
- Potential off-label revenues are negligible due to lack of recent prescribing trends.
- Price erosion typical of off-patent drugs suggests minimal profit margins for new market entrants.
R&D and Repurposing Potential
- Low R&D activity around sulfinpyrazone.
- Repositioning could target new indications such as anti-inflammatory roles or cardiovascular applications, but current scientific evidence is limited.
SWOT Analysis
Strengths
- Established safety profile.
- Low manufacturing costs due to off-patent status.
Weaknesses
- Obsolete market position.
- Lack of patent protection limits competitive differentiation.
Opportunities
- Potential drug repurposing for emerging indications.
- Niche use in specific patient populations resistant to current therapies.
Threats
- Market dominance by newer, more effective drugs.
- Regulatory hurdles for off-label or new indication approvals.
- Competitive generics entry reducing existing profit margins.
Strategic Outlook
Investment viability for sulfinpyrazone is low under current conditions. The drug’s market is dominated by patented, more effective therapies with significant clinical data. Repositioning efforts would require substantial R&D investment without assured success, and regulatory approval pathways remain uncertain. For portfolio inclusion, focus should be on niche indications with emerging evidence or on compounds with stronger patent protection.
Key Takeaways
- Sulfinpyrazone's patent expired decades ago, limiting pricing power.
- The drug has a minimal current market share, primarily in legacy use.
- Opportunities for repositioning are theoretical; scientific evidence remains limited.
- Competitive landscape favors newer uric acid-lowering agents with better efficacy.
- Investment risk remains high given market and regulatory constraints.
Frequently Asked Questions
-
Can sulfinpyrazone be repurposed for new indications?
Scientific evidence supporting new indications is limited. Repositioning would require significant research and regulatory approval.
-
What are recent developments or research trends related to sulfinpyrazone?
No recent major publications or trials suggest active development or new clinical interest.
-
Is sulfinpyrazone still available commercially?
It remains available in some regions as a legacy medication but with negligible sales.
-
What are the main competitors to sulfinpyrazone?
Allopurinol and febuxostat are dominant due to superior efficacy and safety profiles.
-
What regulatory challenges exist for reviving sulfinpyrazone?
Lack of patent protection complicates commercialization; off-label use faces regulatory hurdles.
Sources
[1] Grand View Research. Gout Treatment Market Size, Share & Trends Analysis Report. 2022.
